Business Context and Reporting Period
This Form 6-K filing by Genmab A/S covers the month of February 2026, with the report dated February 23, 2026. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary purpose of this specific filing is to disclose a company announcement regarding transactions connected with the company's share buy-back program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding a corporate action (share buy-back) rather than a financial results report.
Material Changes
The material change disclosed in this filing is the execution of transactions under Genmab A/S's share buy-back program. No comparative financial data or operational changes versus prior periods are detailed in the provided text.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the standard incorporation by reference language. The content is limited to the announcement of the share buy-back transactions.
Investor Verification Checklist
- Verify the specific volume and price of shares repurchased in the transactions referenced in Exhibit 99.1.
- Confirm the remaining authorization limit for the share buy-back program following these transactions.
- Review the full text of the "Company Announcement Dated February 23, 2026" (Exhibit 99.1) for detailed transaction mechanics.